Carnosine
Endogenous dipeptide concentrated in muscle and brain — anti-glycation, antioxidant, pH buffering, and anti-ageing activity.
Research facts
| Half-life | Rapidly hydrolysed by carnosinase (~minutes) |
|---|---|
| Route | Oral (high dose) / IV (experimental) |
| Typical dose | 1–5 g/day orally |
| Frequency | Daily with food |
| Solvent | N/A — oral |
| pH | N/A |
| Stability | Room temperature |
Mechanism of action
Carnosine (beta-alanyl-L-histidine) is an endogenous dipeptide found at high concentrations in skeletal muscle (~20–30 mM) and brain. It acts as an intramuscular pH buffer during high-intensity exercise (the basis for beta-alanine supplementation — its rate-limiting precursor). Beyond buffering, carnosine is a potent anti-glycation agent — it reacts with and detoxifies advanced glycation end-products (AGEs) and methylglyoxal, which are key drivers of diabetic complications and cellular ageing. It scavenges reactive carbonyl species, heavy metals (chelation), and free radicals. Carnosine levels decline ~63% between age 10 and 70.
Documented effects (research-model)
- Anti-glycation — detoxifies AGEs (central to diabetic complications and ageing)
- Intramuscular pH buffering during high-intensity exercise
- Antioxidant and free radical scavenging
- Heavy metal chelation (copper, zinc, lead)
- Neuroprotective in Parkinson's and Alzheimer's animal models
- Oral absorption limited — ophthalmological application for cataracts
Research protocols
| Protocol | Dose | Frequency | Cycle | Vial |
|---|---|---|---|---|
| Standard Oral | 1–2 g/day with meals | Daily with food (reduces carnosinase degradation) | Ongoing | N/A — oral capsule |
Research context only. Not medical advice. Consult a qualified healthcare professional before any protocol decision.
Synergies
- NAD+ MODERATE
Carnosine (anti-glycation, anti-AGE) + NAD+ (mitochondrial energy and sirtuin activation). Complementary anti-ageing mechanisms.
Myths & misconceptions
Evidence gaps
- Optimal delivery method for systemic carnosine elevation (avoiding rapid degradation) not resolved.
- Anti-ageing clinical evidence in humans is limited despite compelling mechanism.
- N-acetylcarnosine (eye drops) is the only form with strong human clinical data (cataract research).
Safety notes
Extremely safe — endogenous metabolite. No significant adverse effects at standard doses. Oral bioavailability limited by carnosinase degradation. Not a regulated compound.
Biomarkers to monitor
Primary-source citations
- PMID 24010695 — Carnosine: An overlooked anti-aging and anti-glycation compound (Rejuvenation Res. 2013)
Frequently asked
What is Carnosine?
Carnosine (Beta-Alanine-L-Histidine — Endogenous Dipeptide) is a research compound classified in our library as Tier C — Limited human trials; effect size uncertain.. Endogenous dipeptide concentrated in muscle and brain — anti-glycation, antioxidant, pH buffering, and anti-ageing activity.
What is the evidence tier for Carnosine?
We classify Carnosine as Tier C: Limited human trials; effect size uncertain. See our full peptide evidence tiers explainer for how we assign S/A/B/C/D.
What is the research dose of Carnosine?
For Carnosine, typical research dose is 1–5 g/day orally, route is Oral (high dose) / IV (experimental), half-life is Rapidly hydrolysed by carnosinase (~minutes). Protocols vary by research goal — see the protocols section on this page for standard and advanced dosing schedules. Research use only, not medical advice.
Is Carnosine safe?
Extremely safe — endogenous metabolite. No significant adverse effects at standard doses. Research context only — no compound on this site is approved for human therapeutic use unless explicitly noted.